These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1138 related items for PubMed ID: 34745015

  • 1. Cancer Stemness-Based Prognostic Immune-Related Gene Signatures in Lung Adenocarcinoma and Lung Squamous Cell Carcinoma.
    Li N, Li Y, Zheng P, Zhan X.
    Front Endocrinol (Lausanne); 2021; 12():755805. PubMed ID: 34745015
    [Abstract] [Full Text] [Related]

  • 2. Identification of Immune-Related Gene Signatures in Lung Adenocarcinoma and Lung Squamous Cell Carcinoma.
    Li N, Wang J, Zhan X.
    Front Immunol; 2021; 12():752643. PubMed ID: 34887858
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Clinically relevant immune subtypes based on alternative splicing landscape of immune-related genes for lung cancer advanced PPPM approach.
    Li N, Jia W, Wang J, Shao Q, Feng X, Li Z, Sun W, Kang M, Hu D, Xing L, Zhan X.
    EPMA J; 2024 Jun; 15(2):345-373. PubMed ID: 38841624
    [Abstract] [Full Text] [Related]

  • 6. Significance of NKX2-1 as a biomarker for clinical prognosis, immune infiltration, and drug therapy in lung squamous cell carcinoma.
    Lin H, Wang J, Shi Q, Wu M.
    PeerJ; 2024 Jun; 12():e17338. PubMed ID: 38708353
    [Abstract] [Full Text] [Related]

  • 7. Integrative stemness characteristics associated with prognosis and the immune microenvironment in esophageal cancer.
    Yi L, Huang P, Zou X, Guo L, Gu Y, Wen C, Wu G.
    Pharmacol Res; 2020 Nov; 161():105144. PubMed ID: 32810627
    [Abstract] [Full Text] [Related]

  • 8. Identification of specific prognostic markers for lung squamous cell carcinoma based on tumor progression, immune infiltration, and stem index.
    Wu R, Ma R, Duan X, Zhang J, Li K, Yu L, Zhang M, Liu P, Wang C.
    Front Immunol; 2023 Nov; 14():1236444. PubMed ID: 37841237
    [Abstract] [Full Text] [Related]

  • 9. Immune- and Stemness-Related Genes Revealed by Comprehensive Analysis and Validation for Cancer Immunity and Prognosis and Its Nomogram in Lung Adenocarcinoma.
    Chen M, Wang X, Wang W, Gui X, Li Z.
    Front Immunol; 2022 Nov; 13():829057. PubMed ID: 35833114
    [Abstract] [Full Text] [Related]

  • 10. Characterization of Cancer Stem Cell Characteristics and Development of a Prognostic Stemness Index Cell-Related Signature in Oral Squamous Cell Carcinoma.
    Feng J, Li Y, Wen N.
    Dis Markers; 2021 Nov; 2021():1571421. PubMed ID: 34840626
    [Abstract] [Full Text] [Related]

  • 11. Deciphering a cell death-associated signature for predicting prognosis and response to immunotherapy in lung squamous cell carcinoma.
    Mao G, Yang D, Liu B, Zhang Y, Ma S, Dai S, Wang G, Tang W, Lu H, Cai S, Zhu J, Yang H.
    Respir Res; 2023 Jul 06; 24(1):176. PubMed ID: 37415224
    [Abstract] [Full Text] [Related]

  • 12. Insights into the heterogeneity of the tumor microenvironment in lung adenocarcinoma and squamous carcinoma through single-cell transcriptomic analysis: Implications for distinct immunotherapy outcomes.
    Fang X, Li D, Wan S, Hu J, Zhang P, Jie D, Chen L, Jiang G, Song N.
    J Gene Med; 2024 Jun 06; 26(6):e3694. PubMed ID: 38847309
    [Abstract] [Full Text] [Related]

  • 13. Differentiated regulation of immune-response related genes between LUAD and LUSC subtypes of lung cancers.
    Chen M, Liu X, Du J, Wang XJ, Xia L.
    Oncotarget; 2017 Jan 03; 8(1):133-144. PubMed ID: 27863400
    [Abstract] [Full Text] [Related]

  • 14. System analysis of FHIT in LUAD and LUSC: The expression, prognosis, gene regulation network, and regulation targets.
    Situ Y, Gao R, Lei L, Deng L, Xu Q, Shao Z.
    Int J Biol Markers; 2022 Jun 03; 37(2):158-169. PubMed ID: 35254116
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. The Tumor Stemness Indice mRNAsi can Act as Molecular Typing Tool for Lung Adenocarcinoma.
    Yi Y, Liu X, Gao H, Qin S, Xu J, Ma F, Guan M.
    Biochem Genet; 2023 Dec 03; 61(6):2401-2424. PubMed ID: 37100923
    [Abstract] [Full Text] [Related]

  • 17. Characterization of a prognostic model for lung squamous cell carcinoma based on eight stemness index-related genes.
    Jiang W, Xie N, Xu C.
    BMC Pulm Med; 2022 Jun 08; 22(1):224. PubMed ID: 35676660
    [Abstract] [Full Text] [Related]

  • 18. Prognostic value of immune-related genes in the tumor microenvironment of lung adenocarcinoma and lung squamous cell carcinoma.
    Qu Y, Cheng B, Shao N, Jia Y, Song Q, Tan B, Wang J.
    Aging (Albany NY); 2020 Mar 25; 12(6):4757-4777. PubMed ID: 32209727
    [Abstract] [Full Text] [Related]

  • 19. Identification of Novel Stemness-based Subtypes and Construction of a Prognostic Risk Model for Patients with Lung Squamous Cell Carcinoma.
    Shen F, Li F, Ma Y, Song X, Guo W.
    Curr Stem Cell Res Ther; 2024 Mar 25; 19(3):400-416. PubMed ID: 37455452
    [Abstract] [Full Text] [Related]

  • 20. GPC3 affects the prognosis of lung adenocarcinoma and lung squamous cell carcinoma.
    Ning J, Jiang S, Li X, Wang Y, Deng X, Zhang Z, He L, Wang D, Jiang Y.
    BMC Pulm Med; 2021 Jun 10; 21(1):199. PubMed ID: 34112123
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 57.